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ABSTRACT 
Background: Traditional drug payment schemes in Catalonia are generally based on the negotiation of fixed 
prices; however, disadvantages arise in the case of innovative therapies. Risk sharing agreements 
distribute potential health and economic uncertainties and high prices on access across the interested parts.  
Objectives: To identify, characterize and analyze current publicly available agreement reports signed by 
the Catalan Health Service and different pharmaceutical companies evaluating the current market access 
scene for new drugs in Catalonia.  
Methods: A database of agreements implemented between 2013 and 2018 was developed by using publicly 
available data. Data analysis was performed in a descriptive way, presenting summaries in datasheets.  
Results: A total of 7 managed entry agreements were analyzed. Two extensions regarding previous 
agreements were also taken into account. The main involved disease area is oncology (57%) and the most 
common length is 1 year, whereas the longest is 3 years.  
Conclusions: Managed entry agreements are gaining popularity and are viewed as positive schemes by 
stakeholders, payers and health services, leading to a general increase of accords during the last years. 
However, there are hardly any studies regarding the impact of RSA post-implementation, a field of great 
relevance regarding health policies. 
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1. INTRODUCTION 
Traditional drug payment schemes in Catalonia regarding both public and private insurances are generally 
based on the negotiation of fixed prices according to the volume of patients that are suitable to obtain and 
benefit from the treatment. When this is the case, it is the buyer who withstands both the economical and 
health-related risk. It is an efficient procedure when comparing the studied drug to commercialized 
alternatives; however, disadvantages arise in the case of innovative therapies. These come in the form of 
drug effectiveness, safety, efficacy in comparison to alternative therapies, economic impact and cost-
effectiveness uncertainties, large budget impacts and the prospect of decreasing marginal benefits [1]. All 
these factors make it difficult to determine new drug price, discouraging market access for innovative drugs 
[2].  
Risk sharing agreements (RSA) or managed entry agreements (MEA) distribute potential health and 
economic uncertainties and high prices on access across the interested parts, in this concrete case, the 
hospital and the pharmaceutical company [3]. An accepted breakdown of RSAs is financial and outcome 
based as first proposed by Adamski et al [4]. There is not one definite classification of these schemes, 
meaning different taxonomies classify models in different manners. The Catalan Health Service (CatSalut) 
differentiates agreements based on economic results and agreements based on clinical results. The latter 
is subcategorized into performance-linked reimbursements (PLR) and conditional reimbursements [1,5]. 
PLRs are also called performance-based risk sharing agreement, payment-by-response, payment-by-
performance, outcomes-based agreements and patient access schemes according to the country or the 
publication [6]. 
The value drivers regarding these agreements can be perceived from both the payer’s and the 
manufacturer’s point of view. While payers are interested in cost reductions, an increase in pharmacy 
discount or reimbursement, reduced final risks and improved patient access; manufacturers are driven by 
an improved level of access, reduced uncertainties regarding long-term benefits and increased revenue [7].  
Most RSAs are for oncology and other high priced products. This is not surprising since prices for oncology 
medicines have raised appreciably in recent years [8,9] despite limited health gain with a number of them 
[10-12]. This situation can only get worse given the high number of cancer medicines in development and 
likely prices despite the fact that the costs of goods can be low for a number of them [13,14]. 
Studies regarding MEA in regions such as Australia, Italy, Sweden, United States, United Kingdom, 
Belgium, the Netherlands, the Middle East, North Africa, Central and Eastern Europe are published [3,7,15-
20]. However, despite an increase in risk-sharing agreements interest in the EU and the subsequent 
inflation of publications [21], the only recent paper concerning MEA in Catalonia refers to a 2011 payment-
by-results agreement regarding gefitinib (Iressa®) and is based on data obtained from an interview [2]. The 
same report is mentioned in a European MEA review in a very non-exhaustive manner [22]. 
Therefore, there is an obvious need to update the available information regarding MEA in Catalonia. Herein 
we identify, source, characterize and analyze current publicly available agreement reports signed by the 
Catalan Health Service (CatSalut) and diverse pharmaceutical companies with the objective of evaluating 
the current market access scene for new drugs in Catalonia.  
2. METHODS 
A database of agreements implemented between 2013 and 2018 was developed using publicly available 
data obtained from the Catalan health department in July 2018. The agreements analysed were obtained 
from the CatSalut web page [23]. A total of 7 MEA and 2 extensions regarding previous agreements were 
analyzed throughout the study. These MEA involved 9 pharmaceutical companies, 9 drugs and 8 different 
indications. A descriptive data analysis was performed, presenting summaries in datasheets and values in 
percentage form.  
The following information was gleaned from the dossiers and was considered in the descriptive analysis: 
report date, agreement type, agreement length, drug name, active ingredient, pharmaceutical company, 
indication, inclusion criteria, exclusion criteria, time to response evaluation, response evaluation criteria, 
result evidence, patient classification by response, economic conditions, reimbursement and if the 
agreement has been extended.    
3. RESULTS 
In this study only two types of MEA were identified. They correspond to performance-linked reimbursement 
(PLR), defined as the return of a product or economic value according to the clinical outcomes of the 
treatment, and risk sharing agreements (RSA), specifying an explicit expenditure ceiling.  
The earliest agreement analyzed was signed in 2013 [24]. It corresponds to a PLR agreement between the 
University Hospital of Bellvitge and a pharmaceutical company for the use of certolizumab pegol combined 
with methotrexate in the population with rheumatoid arthritis when the response to disease-modifying anti-
rheumatic drugs (including methotrexate) has been inadequate. In this case, the hospital only paid for those 
patients included that the program reached an optimal clinical response in week 12 according to the clinical 
variables established in the agreement (Table 1). According to the contract, there was a previous PLR 
agreement between the pharmaceutical company and Hospital Clinic de Barcelona dated 5 November 2012 
for the use of certolizumab pegol in the treatment of rheumatoid arthritis. 
The first agreement extension analyzed was signed also in 2013 [25] and corresponds to a one-year 
prolongation of the convention singed in July 2011 between a pharmaceutical company, CatSalut and 
Catalan Institute of Oncology (ICO) (Table 2). It was agreed to administer tyrosine kinase protein inhibitors 
to patients with first-line metastatic non-small cell lung cancer, seen at any of the ICO centers. 
In 2017, five PLR agreements and one extension were signed (Table 3). The first PLR was signed between 
a pharmaceutical company and CatSalut for the use of panitumumab in adult patients with metastatic 
colorectal carcinoma (mCRC) with non-mutated RAS (wild-type) in the first line in combination with 
FOLFOX (fluorouracil, leucovorin, oxaliplatin) [26]. In this case the hospitals only paid for those patients 
with no disease progression in week 12+/-1(Table S1). The second PLR involved a pharmaceutical 
company and CatSalut and agreed to use pembrolizumab in patients diagnosed with advanced melanoma 
(metastatic or unresectable) [27]. In this case, the reimbursement depended on the percentage of patients 
who interrupted the treatment during the first 4 cycles of the total number of patients included (Table S2). 
The third PLR agreement was signed between a pharmaceutical company and CatSalut for the use of 
fampridine for the improvement of gait in patients with multiple sclerosis with gait disability [28]. The 
hospitals paid only for those patients who maintained 3 months the improvement observed at two weeks 
according to the criteria established in the agreement (Table S3). The fourth PLR involved a pharmaceutical 
company and CatSalut, and agreed the use of pertuzumab in combination with trastuzumab in the 
neoadjuvant treatment of HER2 positive breast cancer [29]. The pharmaceutical company will only assume 
the full cost of pertuzumab used in the neoadjuvant treatment, in combination with trastuzumab and 
chemotherapy, of that proportion of patients that do not reach clinical response (patients with stable or 
progressive disease, according to RECIST criteria) (Table S4). The last PLR agreement was signed 
between a pharmaceutical company and CatSalut for the use of trametinib in combination with dabrafenib 
in the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation [30]. 
In this case, the pharmaceutical company will assume the treatment cost for those patients considered non-
responders because of the suspension of treatment due to having experienced progression of the disease 
or unmanageable adverse effects with temporary interruption and / or dose reduction, causing definitive 
discontinuation of the treatment during the first 12 weeks (+/- 2 weeks depending on real clinical practice) 
of treatment (Table S5).  
The only agreement extension signed in 2017 corresponds to a one-year prolongation of the convention 
signed in April 2016 between a pharmaceutical company and CatSalut for the use of cetuximab in the first 
line of treatment in metastatic colorectal cancer (Table 2) [31].  
Finally, one RSA was signed in 2018 between a pharmaceutical company and CatSalut for the use of 
tolvaptan in patients with rapidly progressive autosomal dominant polycystic kidney disease (ADPKD) [32]. 
In this case, the payment scheme will be based on an annual expenditure ceiling for treatments with 
tolvaptan (Table 4). Once the annual expenditure ceiling established for each calendar year has been 
reached, the pharmaceutical company will assume the cost of treatment with tolvaptan that exceeds this 
ceiling. 
In a more descriptive way, we have identified 5 agreements within the scope of oncology diseases, which 
encompass 57.1% of the studied agreements. These reports refer to colorectal, melanoma, HER2+ breast 
cancer and non-small cell lung cancer. 
In general, PLR schemes analyzed have a validity period of 1 year, with the possibility to extend the 
agreement annually up to a maximum of 4 years, including the original agreement period. There are some 
agreements with a larger validity period, as the agreement regarding multiple sclerosis with a validity period 
of 2 years, and the RSA related to ADPKD with a validity period of 3 years. Both agreements can also be 
expanded up to a maximum of 4 years. As expected, following the same norm, both agreement extensions 
are active over a period of 12 months (Table 4).  
Inclusion criteria and clinically relevant result evidence include biochemical tests, imaging, disease 
morphology, physical and mobility tests, functional state, scoring and descriptive criteria. These are studied 
according to the disease and treatment of interest. In some cases, such as the signed agreement regarding 
pertuzumab + trastuzumab or panitumumab + folfox inclusion criteria are very similar to the inclusion criteria 
of clinical trials concerning the same drugs. Rather, other agreements include very ambiguous inclusion 
and exclusion criteria or less specific descriptions.  
Regarding time to clinical results or outcome measurements, it varies across agreements. Whilst some 
measurements are obtained as soon as 2 weeks after treatment initiation, others are evaluated 5 to 6 
months later.  Four of the reports [24,26,27,30] indicate evaluation should be reported within 12 weeks of 
the start of the treatment, one of them being described in relation to treatment cycles.  
Finally, drug price for reimbursement were not broadly specified in most agreements, which simply stated 
that the price is associated to ex-factory price plus value added tax (VAT) with a 7.5% discount (RD 
08/2010). Only three of the MEA indicate the exact price of drugs including: fampridine, panitumumab and 
the expenditure ceiling established for tolvaptan. 
4. DISCUSSION 
These results are in accordance with an international review describing PLRs as, currently, the most 
common MEA having overtaken coverage with evidence development agreements since 2012. Most 
reviewed publications agree also with the areas of disease related to such MEA taking into account that 
41% of reports concerned oncology drugs and 8% rheumatology treatments [3,15]. 
Even though the information is limited the trend line suggests that older agreements (i.e. 2013) were signed 
with individual hospitals whereas more recent MEA were signed with CatSalut, which implies the agreement 
implementation in the entire public healthcare system in Catalonia (SISCAT). Although in most cases we 
cannot know what ensued after the initial agreement, this suggests success of the first scheme 
implementations. Such assumption is supported by the fact that many interviewed healthcare professionals 
in Spain and European pharmaceutical decision makers and stakeholders, expect MEA to increase in the 
future, in particular PLRs [33]. The main reasons are the greater reduction in total cost and the increase in 
uncertainty management that these agreements provide [34]. Although global trends have varied over time 
and seem to be back on the rise after a slowdown in 2013–2014, the number of RSAs in the UK has 
decreased, opting more often for confidential discounts [15].  
However, partly attributed to the inconsistent published reports and the difficulties that arise from controlling 
outcomes in real-world environments, there are hardly any studies regarding the impact of RSA post-
implementation, a field of great relevance regarding health policies, which is also an issue in other regions 
[2,35,36]. 
On a general note, and based on the agreements included in this study, a variety of pharmaceutical 
companies have been involved in signing MEA for innovative drugs, contributing to new marked access 
schemes in Catalonia.   
Regarding the validity period of MEA, Central and Eastern European countries share similar validity periods 
ranging from 1 to 5 years, 2 years being the average length [3].  
Regarding limitations of this study, we cannot know whether there has been an increase in MEA in Catalonia 
or not, because not all MEA were public we cannot know the number or characteristics of non-published 
agreements. The studied reports correspond to those publicly accessible during July 2018, however a more 
rigorous analysis could be developed if all MEA were published and recollected. In addition, information 
about what ensued after the initial agreement was unavailable. In future research we might contact different 
stakeholders to hear about their assessment of these MEAs in order to obtain unavailable information.     
5. CONCLUSION 
MEA are gaining interest internationally amongst stakeholders, pharmaceutical companies and national 
healthcare centers, particularly RSA and PLRs. This trend is also observed in the Spanish region of 
Catalonia where a significant growth in patient access schemes mostly regarding oncology treatments is 
observable since 2011 when the first payment-by-results agreement was signed in regards to metastatic 
non-small cell lung cancer. However, partly attributed to the inconsistent published reports and the 
difficulties that arise from controlling outcomes in real-world environments, there are hardly any studies 
regarding the impact of RSA post-implementation, a field of great relevance regarding health policies, which 
is also an issue in other regions. 
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Table 1 Managed entry agreements signed in Catalonia in 2013 
Report date May 2013 
Agreement type Performance-linked reimbursement 
Agreement 
length 
1 year (can be renewed annually) 






UCB Pharma S.A. 
Indication Rheumatoid arthritis 
Inclusion 
criteria 
RA patients naive to biological drug therapy 
• ACR 2010 criteria 
• Inadequate response to FAMM (including methotrexate) 








Good response:  
• DAS-28 < 2.6 and <3.2 in terms of remission or low activity 
• For evolved disease: 3.2 < DAS-28 < 5.1 (when the reduction is significant) 
Economic 
conditions 
Ex-factory price + VAT + 7.5% disc. 
Reimbursement 
Trimestral restocking of the drug supplies used by patients up to week 12 if optimal 
clinical response hasn’t been reached 
Institution Bellvitge University Hospital (Catalonia) 
Reference (24) 
ACR American college of Rheumatology, DAS-28 Disease Activity Score 28, VAT value added tax 





























PLR Performance-linked reimbursement, RSA Risk-sharing agreement 
 
  












Indication Institution Reference 
Mar-17 PLR 1 year 







First line treatment 
for adult patients with 
colorectal metastatic 
cancer with wild type 
RAS 
CatSalut (26) 
Mar-17 PLR 1 year KEYTRUDA®  Pembrolizumab 
Merck Sharp & 
Dohme de 










with motor disability 
CatSalut (28) 








treatment of HER2+ 
locally advanced, 
inflamatory or early 
stage with a high 

















BRAF V600 mutation  
CatSalut (30) 
PLR Performance-linked reimbursement  
Table 4 Managed entry agreements signed in Catalonia in 2018 
Report date April 2018 
Agreement 
type 
Risk sharing agreement 
Agreement 
length 
3 years (can be renewed annually up to a maximum of 4 years) 






Otsuka Pharmaceutical S.A. 
Indication Rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) 
Inclusion 
criteria 
• 50 years or less 
• Stage 1-3a chronical kidney disease: 
o 18-30 years: stage 1-3a (eGFR > 45 ml/min/1.73 m2)  
o 30-40 years: stage 2-3a (eGFR = 45-90 ml/min/1.73 m2)  
o 40-50 years: stage 3a (eGFR = 45-60 ml/min/1.73 m2)  
• Rapid progressions: 
o Decrease of eGFR > 5 ml/min/1,73 m2 in a year and/or > 2.5 
ml/min/1,73 m2 during 5 years (CKD-EPI) 
o Annual increase of total kidney volume > 5% measured with NMR at 
least 3 times (with 6 months between measurements)  









The pharmaceutical company will assume the cost of the treatment that exceeds the 
expenditure ceiling 
Institution CatSalut  
Reference (32) 
eGFR estimated glomerular filtration rate, CDK-EPI Chronic Kidney Disease Epidemiology Collaboration, VAT value added tax
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SUPPLEMENTARY INFORMATION  
Table S1 Managed entry agreements signed in Catalonia in 2017 (VECTIBIX® + FOLFOX®) 
Report date Mar-17 
Agreement type Performance-linked reimbursement  
Agreement length 1 year (can be renewed annually up to a maximum of 4 years) 
Drug name VECTIBIX®  + FOLFOX® 
Active ingredient 
Panitumumab + fluorouracil, leucovorin, oxaliplatin 
Pharmaceutical 
company AMGEN S.A. 
Indication 
First line treatment for adult patients with colorectal metastatic cancer with wild type RAS 
Inclusion criteria • ≥ 18 year olds 
•  Histological evidence of colorectal metastatic cancer 
• Wild type RAS (KRAS/NRAS) 
• First-line Folfox + panitumumab treatment 
• Disease measurable by RECIST 1.1 
• Functional activity degree ECOG from 0-1 
Exclusion criteria • Previous chemotherapy (or other treatment against colorectal metastatic cancer). 
Except for adjuvant chemotherapy based on fluoroprimidines or oxaliplatin 
dispensed at least 6 and  12 months prior to the start of the treatment, respectively 
• Previous treatment with anti-EGFR antibodies or small molecule EGFR inhibitors 
Time to response 
evaluation 
Week 12 (+/-1) since the start of the treatment  
(measures at week 10 and 14 will also be considered valid) 
Response 
evaluation criteria 
• RECIST criteria 
• Thorax, abdomen and pelvis CT scan  
• Radiology progression report 





- Progression of the disease at week 12 (+/- 1) according to RECIST 1.1. 
- Suspicious symptoms of progression before week 12 (+/- 1) are evaluated.  
- Treatment modifications previous to the 12 (+/-1) week mark.                                     
- Tumor progression or secondary to adverse effects exitus.  
Economic 
conditions 
Vectibix ® (400 mg): 1,444.96€ (7.5% disc). 
Vectibix ® (100 mg): 361.24€ (7.5% disc) 
Reimbursement Payment value or a quantity of vials equivalent to the total of consumed vials by non-
responding patients up to the time of evaluation (12 weeks) will be reimbursed to the 
hospital. Exclusion: Change of treatment strategy prior to week 12 
Institution Catsalut 
Reference (26) 
RECIST Response evaluation criteria in solid tumors, ECOG Eastern Cooperative Oncology Group, EGFR Epidermal growth factor receptor , CT 
computered tomograophy, NMR nuclear magnetic resonance    
Table S2 Managed entry agreements signed in Catalonia in 2017 (KEYTRUDA®) 
Report date Mar-17 
Agreement type Performance-linked reimbursement 
Agreement length 1 year (can be renewed annually up to a maximum of 4 years) 





Merck Sharp & Dohme de España S.A.  
Indication 
Advanced unresectable metastatic melanoma 
Inclusion criteria Patients with advanced unresectable metastatic melanoma in a good functional state that 
meet at least one of the following criteria: 
• without BRAF mutation that haven’t been treated previously 
• +BRAF mutation with normal LDL levels and without  clinically significant symptoms 
of tumor progression that haven’t been treated previously 
•  +BRAF mutations that have been treated with +/-BRAF or MEK inhibitor, that are 
candidates for second line treatment with pembrolizumab 
Time to response 




• Disease stage 
• Functional state according to ECOG 
• HDL levels 
Economic 
conditions 7.5% disc. 
Reimbursement Effective if treatment is interrupted within the first 4 cycles  
Payment calculation: 
• 15-45% interruption: drug payment will be calculated according to the total 
number of vials consumed by all the patients that have interrupted treatment 
during the first 4 cycles 
• ≥45%: calculated over the mean number of vials/patient that have interrupted 
treatment during the first 4 cycles by 45% of patients 
• ≤15%: calculated over the mean number of vials/patient that have interrupted 
treatment during the first 4 cycles by 15% of patients 
Institution CatSalut 
Reference (27) 
ECOG Eastern Cooperative Oncology Group, LDL low density lipoprotein, HDL high density lipoprotein  
Table S3 Managed entry agreements signed in Catalonia in 2017 (FAMPYRA®) 
T25FW Timed 25-Foot Walk, 2MWT Two minute walk test, MSWS-12 scale multiple sclerosis walking scale 
  
Report date Mar-17 
Agreement type Performance-linked reimbursement 
Agreement length 2 years (can be renewed annually up to a maximum of 4 years) 
Drug name FAMPYRA®  
Active ingredient Fampridine 
Pharmaceutical 
company 
Biogen Spain S.L. 
Indication Multiple sclerosis with motor disability 
Inclusion criteria Patients with multiple sclerosis and motor disability that are susceptible to be treated with 
fampridine 





• T25FW Improve walking velocity in 25% 
• 2MWT Improve in 25% (if the patient cannot take this test, 15% improvement for 
"up and go" test) 





Patients who maintain the observed week-2 improvements after 3 months 
Economic 
conditions 
Ex-factory price: 192.31€ 
- 7.5% disc.: 177.89€ 
+4% VAT: 185.00€ 
Reimbursement 
If response is not maintained after 3 months the pharmaceutical company will assume the 
total cost of the 3-month treatment 
Institution CatSalut 
Reference (28) 
Table S4 Managed entry agreements signed in Catalonia in 2017 (PERJETA® + HERCEPTIN®) 
Report date May-17 
Agreement type Performance-linked reimbursement 
Agreement length 1 year (can be renewed annually up to a maximum of 4 years) 
Drug name PERJETA® + HERCEPTIN® 
Active ingredient 
Pertuzumab + trastuzumab 
Pharmaceutical 
company Roche Farma S.A. 
Indication Neaoadjuvant treatment of locally advanced, inflammatory or early stage with a high relapse 
risk HER2+ breast cancer in combination with chemotherapy 
Inclusion criteria 
• Patients with HER2+ tumors evidenced by IHC·+ or FISH / CISH 
• Locally advanced tumor, inflammatory or ≥2cm in diameter or axillary lymph node 
affectation 
• ECOG 0-1 
Exclusion criteria 
• Patients with a cardiopathy that prevents them from using trastuzumab 
• LVEF ≤ 50% 
• Patients with disease that isn't considered to have a high risk of relapse 
Time to response 
evaluation 
Treatment duration (5-6 months)  
Response 
evaluation criteria Complete pathological response (ypT0 / is ypN0) in breast and armpit 
Reimbursement The pharmaceutical company will assume all cost only when patients do not achieve clinical 
response (stable disease or progression according to RECIST criteria). 
 
Packets of Herceptin IV or/and SC will be administered to the hospital according to an 
equivalent cost of Perjeta®. 
 
Fractioned packages will be accumulated for return until the following period. 
Institution CatSalut 
Reference (29) 






Table S5 Managed entry agreements signed in Catalonia in 2017 (MEKINIST® + TAFINLAR®) 
Report date Jun-17 
Agreement type Performance-linked reimbursement 
Agreement length 1 year (can be renewed annually up to a maximum of 4 years) 
Drug name MEKINIST® + TAFINLAR® 
Active ingredient 
Trametinib + dabrafenib 
Pharmaceutical 
company Novartis Farmacéutica S.A.  
Indication 
Advanced unresectable metastatic melanoma with BRAF V600 mutation  
Inclusion criteria 
Advanced unresectable metastatic melanoma with no previous treatment 
• Confirmed BRAF V600 mutation  
• ECOG 0-1 (ECOG 2 if related to the disease symptomatology) 
Exclusion criteria 
• Patients in risk of retinal vein occlusion or central serous retinopathy 
• Patients with uveal melanoma 
• Patients with untreated  active cerebral metastasis  
• Patients treated with BRAF inhibitor 
Time to response 
evaluation 12 weeks (+/- 2) 
Response 
evaluation criteria 





Patient with definite discontinuation of treatment during the first 12 weeks due to disease 
progression 
Economic 
conditions Ex-factory price + VAT (+ 7.5% disc.) 
Reimbursement 
Effective by semester if disease progresses and/or patient presents severe adverse effects 
and/or intolerance leading to treatment discontinuation before week 12  
Institution CatSalut 
Reference (30) 
ECOG Eastern Cooperative Oncology Group, RECIST Response evaluation criteria in solid tumors, VAT value added tax 
 
